FDA Approved Brigatinib Drug For Lung Cancer Treatment
Cancers caused due to the abnormal proliferation of the cells in the lungs are referred to as Lung cancer. Around 3-5% of lung cancers are caused due to the changes in gene Anaplastic lymphoma kinase (ALK). Brigatinib drug receives approval from FDA to treat ALK-positive lung cancer as second-line therapy.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer